Document is current

Any future updates will be listed below

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

Crossref DOI link: https://doi.org/10.1186/s40164-019-0128-y

Published Online: 2019-02-01

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark